...
首页> 外文期刊>Oncogene >Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK|[sol]|p38 and mitochondrial death pathway
【24h】

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK|[sol]|p38 and mitochondrial death pathway

机译:死亡受体抗体和化疗剂通过JNK | [sol] | p38和线粒体死亡途径协同诱导肿瘤细胞凋亡

获取原文
           

摘要

Using two agonistic monoclonal antibodies specific for each death receptor of TRAIL, 2E12 (anti-human DR4) and TRA-8 (anti-human DR5), we examined the signal transduction of the death receptors in combination with or without Q1chemotherapy agents such as Adriamycin (doxorubicin hydrochloride) and Cisplatin. Our results demonstrated that chemotherapy agents were able to enhance apoptosis-inducing activity of these antibodies against several different types of tumor cell lines through enhanced caspase activation. The combination of the antibodies and chemotherapy agents led to a synergistical activation of the JNK/p38 MAP kinase, which was mediated by MKK4. The combination also caused an increased release of cytochrome c and Smac/DIABLO from mitochondria in parallel with the profound loss of mitochondrial membrane potential. These results suggest that the enhanced activation of the JNK/p38 kinase and the mitochondrial apoptosis pathways play a crucial role in synergistic induction of the death receptor-mediated apoptosis by chemotherapy agents. Thus, the simultaneous targeting of cell surface death receptors with agonistic antibodies and the intracellular JNK/p38 and the mitochondrial death pathways with chemotherapy agents would enhance the efficacy and selectivity of both agents in cancer therapy.
机译:使用两种特异于TRAIL,2E12(抗人DR4)和TRA-8(抗人DR5)每个死亡受体的激动性单克隆抗体,我们结合或不与Q1化疗药物(例如阿霉素)一起检查了死亡受体的信号转导。 (盐酸阿霉素)和顺铂。我们的结果表明化学治疗剂能够通过增强caspase激活来增强这些抗体针对几种不同类型肿瘤细胞系的凋亡诱导活性。抗体和化学治疗剂的组合导致JNK / p38 MAP激酶的协同激活,这由MKK4介导。这种组合还导致线粒体细胞色素c和Smac / DIABLO的释放增加,同时线粒体膜电位也大大降低。这些结果表明,JNK / p38激酶的激活增强和线粒体凋亡途径在化学药物协同诱导死亡受体介导的凋亡中起着至关重要的作用。因此,用激动剂抗体和细胞内JNK / p38同时靶向细胞表面死亡受体和用化疗剂同时靶向线粒体的死亡途径将增强这两种试剂在癌症治疗中的功效和选择性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号